サウスダコタにおける卵巣がんの臨床試験
サウスダコタ内の拠点で、卵巣がんに関する16件の研究が参加者を募集しています。
サウスダコタ内の都市
公式研究テキスト（英語）
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Sanford Health, Sioux Falls
被験者募集中第3相
18歳以上 · 女性 · 2026/10/05更新 · NCT06915025Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中第2相
全年齢 · 全性別 · 2026/10/05更新 · NCT05564377A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Avera Medical Group, Sioux Falls
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Sanford Cancer Center /ID# 274901, Sioux Falls
- Avera Cancer Institute - Sioux Falls /ID# 276226, Sioux Falls
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0132 - Avera Cancer Institute, Sioux Falls
被験者募集中第2相
18歳以上 · 女性 · 2026/09/29更新 · NCT05128825A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Avera Cancer Institute - Sioux Falls /ID# 278627, Sioux Falls
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07059845Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Sanford Cancer Center-Sioux Falls, Sioux Falls
被験者募集中第3相
18歳以上 · 女性 · 2026/09/15更新 · NCT07214779Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Avera Cancer Institute Sioux Falls, Sioux Falls
被験者募集中第2相
18歳以上 · 女性 · 2026/09/14更新 · NCT06787612A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Site 0112, Sioux Falls
被験者募集中第3相
18歳以上 · 女性 · 2026/08/12更新 · NCT07546500A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Sanford Cancer Center Oncology Clinic, Sioux Falls
- Sanford USD Medical Center - Sioux Falls, Sioux Falls
被験者募集中
35歳〜50歳 · 女性 · 2026/08/07更新 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Avera Cancer Institute-Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute at Pierre, Pierre
- 他4件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/07更新 · NCT06580314A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Sanford Cancer Center Gynecologic Oncology, Sioux Falls
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06161025A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Sanford Cancer Center, Sioux Falls
- Sanford USD Medical Center, Sioux Falls
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Avera Medical Group Gynecologic, Sioux Falls
被験者募集中第3相
18歳以上 · 女性 · 2026/07/02更新 · NCT06819007A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Avera Cancer Institute, Sioux Falls
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996Avera Cancer Sequencing and Analytics Protocol (ASAP)
- Avera Cancer Institute - Aberdeen, Aberdeen
- Avera Cancer Institute - Mitchell, Mitchell
- Avera Cancer Institute - Pierre, Pierre
- 他2件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/27更新 · NCT05142033ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。